The integration of GLP-1 medications into comprehensive treatment plans offers a powerful tool for managing patients with coexisting obesity, diabetes, and sleep disorders
Most GLP-1 receptor agonists are administered subcutaneously once weekly (semaglutide, dulaglutide, tirzepatide) or once daily (liraglutide), though frequency varies by specific medication
We report our methods and results in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement for network meta-analyses [10]
Supports Cellular Health Promotes overall cell health and regeneration, improving vitality and energy levels
Nat Rev Mol Cell Biol 2009;10:63743
[1] [4] It works by mimicking the action of the naturally occurring hormone GLP-1, which stimulates insulin secretion in response to food intake, suppresses glucagon release, slows gastric emptying, and reduces appetite through central nervous system pathways